The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | A promising future for drug development in gastrointestinal cancer
Hani Babiker, MD, of the University of Arizona Cancer Center, Tucson, AZ, is excited by the rapid progress being made in drug development for gastrointestinal cancers, particularly colorectal cancer (CRC). However, Dr Babiker also expresses the need for more lines of therapy to fight CRC now that patients are living longer. From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Dr Babiker is hopeful that clinical trial participation for drugs to fight CRC will increase, and uses the progress in pancreatic cancer survival over the last 5years as an example to highlight a promising future for gastrointestinal cancer treatment.
